And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...

Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM ESTCompany ParticipantsJohn Gallagher - SVP, Principal ...

Earnings call ACC reported a 58% YoY rise in EBITDA to ₹1,761 crore and a 364% jump in PAT to ₹2,302 crore, driven by 20% volume growth and strong cost control. Management raised its FY28 capacity ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Thank you for standing by. My name is Tina, and I will be your ...

Earnings call Ambuja Cements reported Q2 FY26 revenue of ₹9,174 crore, up 21% YoY, and EBITDA of ₹1,761 crore, up 58% YoY. Volume grew 20% YoY, outpacing the industry’s 4%. Management reaffirmed FY28 ...

Future expense trends -- Both SG&A and R&D are anticipated to rise starting in Q4 2025 as the company invests in commercial expansion and clinical development.

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

Operator: Good morning. Welcome to Kamada Ltd. third quarter 2025 earnings conference call. At this time, all participants ...

Adjusted EBITDA -- $11.7 million, up 34% from the comparable 2024 quarter. Portfolio Drivers -- Revenue growth was driven by ...

Q3 2025 Earnings Call Transcript November 6, 2025 Operator: Welcome to the Curtiss-Wright Third Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to ...

ACC Ltd reported its Q2 FY26 earnings, revealing a mixed financial performance that saw the company surpass revenue expectations but fall short on earnings per share (EPS). Despite achieving its ...